We had reported that the presence of the GFI1-36N protein was associated with an increased incidence of mutations in genes encoding epigenetic modifiers such as DNMT3a and could be therapeutically exploited in AML therapy (2, 15). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.